ID
22015
Description
Study part: Protocol exceptions. A phase III multinational, randomized, single-blind study of recombinant humanized anti-p185HER2 monoclonal antibody (rhuMAb HER2) in patients with HER2/neu overexpression who have not received prior cytotoxic chemotherapy for metastatic breast cancer. "Terms of use: You may not use this document or the information contained herein to a regulatory authority in connection with an application for a marketing authorization or any other regulatory submission without the express written consent of Roche"
Keywords
Versions (1)
- 5/14/17 5/14/17 -
Copyright Holder
Roche
Uploaded on
May 14, 2017
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
PROTOCOL EXCEPTIONS Roche H0650g Breast Cancer
PROTOCOL EXCEPTIONS
- StudyEvent: ODM
Description
2. IF YES. PLEASE INDICATE THE NUMBER(S) OF ELIGIBILITY CRITERIA FROM THE WORKSHEET WHICH WERE NOT SATISFIED AND PROVIDE A BRIEF DESCRIPTION OF EACH. PL.EASE ALSO SPECIFY THE NAME OF THE EMPLOYEE CONTACTED FOR APPROVAL AND THE DATE APPROVAL WAS OBTAINED
Description
Eligibility Criteria
Data type
text
Alias
- UMLS CUI [1]
- C1516637
Description
description Eligibility Criteria
Data type
text
Alias
- UMLS CUI [1,1]
- C0678257
- UMLS CUI [1,2]
- C1516637
Description
investigator name
Data type
text
Alias
- UMLS CUI [1]
- C2826892
Description
DATE OF CONTACT
Data type
date
Alias
- UMLS CUI [1,1]
- C0011008
- UMLS CUI [1,2]
- C0332158
Description
Investigator name
Data type
text
Alias
- UMLS CUI [1]
- C2826892
Similar models
PROTOCOL EXCEPTIONS
- StudyEvent: ODM
C0545082 (UMLS CUI [1,2])
C1516637 (UMLS CUI [1,2])
C0332158 (UMLS CUI [1,2])